Bioprocess Automation Market : Technology Advancements, Industry Insights, Trends And Forecast 2033

Overview and Scope
Bioprocess automation is using automated systems to monitor and control the bioprocessing workflow, which involves living cells, organisms, or components to produce biological products such as biopharmaceuticals. Biopharmaceutical businesses use bioprocess automation for better process control and optimization, higher product quality, decreased variability, increased throughput and efficiency, cost savings, and scalability.

Sizing and Forecast
The bioprocess automation market size has grown rapidly in recent years. It will grow from $5.01 billion in 2023 to $5.67 billion in 2024 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increased efficiency, cost reduction, risk mitigation, rising demand for remote monitoring and control, and reduced labor dependency.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/bioprocess-automation-global-market-report

The bioprocess automation market covered in this report is segmented –

1) By Component Of Process Control System: Sensors, Actuators, Controllers
2) By Scale Of Operation: Preclinical Operations, Clinical Operations, Commercial Operations
3) By Mode Of Operation: Batch, Fed-Batch, Perfusion
4) By Compatibility With Bioprocessing Systems: Single-Use Systems, Stainless Steel, Other Bioprocessing Systems

North America was the largest region in the bioprocess automation market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess automation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=14058&type=smp

Major Driver Impacting Market Growth
The increasing number of personalized medicines is expected to fuel the growth of the bioprocess automation market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, practices, interventions, and treatments to the individual characteristics of each patient. Bioprocess automation helps personalized medicine by enabling precision and scalability in producing patient-specific drugs. For instance, according to Personalized Medicine Coalition, a US-based professional membership organization, in 2022, approving 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the increasing number of personalized medicines is driving the growth of the bioprocess automation market.

Key Industry Players
Major companies operating in the bioprocess automation market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Corporation, Danaher Corporation, Amgen Inc., Merck KGaA , Parker-Hannifin Corporation, CSL Behring LLC, Rockwell Automation Inc., Agilent Technologies Inc. , Lonza Group AG, Waters Corporation , Getinge AB, Eppendorf AG, Repligen Corporation, BIONET Research S.A., Flotek Industries Inc., Pierre Guerin SAS, Bioengineering AG, Genedata AG, ILS Automation, INFORS AG , Synthace Limited, Automated Control Concepts Inc., BlueSens gas sensor GmbH, DISTek Integration Inc., Securecell AG, Flownamics Analytical Instruments Inc., Inscripta Inc., PendoTECH Inc., Sartorius Stedim Biotech S.A.

The bioprocess automation market report table of contents includes: